5-碘-1H-吲哚唑-3-甲酸 | 1077-97-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 5-碘-1H-吲哚唑-3-甲酸
• 英文名称: 5-iodoindazole-3-carboxylic acid
• 英文别名: 5-iodo-1(2)H-indazole-3-carboxylic acid；5-Iodo-1H-indazole-3-carboxylic acid；5-iodo indazole-3-carboxylic acid；3-carboxy-5-iodo-1H-indazole；5-Iod-3-carboxy-indazol
• CAS: 1077-97-0
• 化学式: C₈H₅IN₂O₂
• mdl: MFCD05663985
• 分子量: 288.044
• InChiKey: VRWNCSJMDOUQJT-UHFFFAOYSA-N

物化性质

• 熔点：
  375℃
• 沸点：
  512.1±30.0 °C(Predicted)
• 密度：
  2.220±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Iodo-1h-indazole-3-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Iodo-1h-indazole-3-carboxylic acid
CAS number: 1077-97-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5IN2O2
Molecular weight: 288.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-碘-1H-吲哚唑-3-甲酸 在 Oxone 、 sodium tetrahydroborate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 水 、 potassium acetate 、 potassium carbonate 、 caesium carbonate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 、 丙酮 、 乙腈 为溶剂， 反应 43.0h， 生成 N-[3-(hydroxymethyl)-2-oxopyrrolidin-3-yl]-2-methyl-5-[(4-methyl-1,3-thiazol-5-yl)methoxy]-2H-indazole-3-carboxamide
  参考文献：
  名称：

  [EN] INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS
  [FR] DÉRIVÉS D'INDAZOLE POUR LE TRAITEMENT DE TROUBLES MÉDIÉS PAR TRPM3

  摘要：

  本发明涉及可用于预防或治疗TRPM3介导的疾病的化合物，尤其是可用于预防或治疗选自疼痛和炎症性超敏反应的疾病的化合物。本发明还涉及一种预防或治疗上述TRPM3介导的疾病的方法。

  公开号：

  WO2023230540A2
• 作为产物：
  描述：

  5-氨基-1H-吲哚唑-3-甲酸 在 sodium nitrite 、 potassium iodide 作用下， 以 硫酸 为溶剂， 反应 25.25h， 以67%的产率得到5-碘-1H-吲哚唑-3-甲酸
  参考文献：
  名称：

  由 5-卤代吲唑鎓-3-羧酸盐脱羧生成的 5-卤代吲唑的 N-杂环卡宾

  摘要：

  描述了作为拟交叉共轭杂环内消旋甜菜碱的新代表的 5-氟-、氯-溴-和碘-取代的 1,2-二甲基吲唑鎓-3-羧酸酯的合成和性质，以及 X 射线的结果提供了非卤化母体化合物的单晶分析。这些甜菜碱在加热时脱羧生成 5-halo-1,2-二甲基-吲唑-3-ylidenes，它们可以分别被质子、硫和 2,4-二氯苯基异氰酸酯捕获。通过电喷雾电离质谱、核磁共振光谱、热重分析和差示扫描量热法研究脱羧。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)

  DOI：

  10.1002/ejoc.200700192

文献信息

• [EN] 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS<br/>[FR] COMPOSES 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE KINASES CYCLINE-DEPENDANTES (CDK)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2004014864A1

  公开（公告）日：2004-02-19

  The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R2 or CH2-R2 where R2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R1 is hydrogen or a group selected from SO2Rb,SO2NR7R8,CONR7R8,NR7R9 and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R3, to R9 are defined in the description but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.

  本发明提供了一种式(I)化合物，用于预防或治疗由细胞周期蛋白依赖性激酶介导的疾病状态或条件：其中A是R2基团或CH2-R2，其中R2是具有3至12个环成员的碳环或杂环基团；B是键或具有最多3个原子（选自C、N、S和O）的链长的不饱和链连接基团；R1是氢或选自SO2Rb、SO2NR7R8、CONR7R8、NR7R9以及具有3至7个环成员的碳环和杂环基团；R3至R9在说明书中定义，但不包括化合物N-[(吗啉-4-基)苯基-1H-吲唑-3-甲酰胺]和N-[4-(乙酰氨基磺酰基)苯基-1H-吲唑-3-甲酰胺]。
• Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors
  申请人：D'Orchymont Hugues

  公开号：US20060004000A1

  公开（公告）日：2006-01-05

  Compound corresponding to general formula (I): in which, R 1 represents a hydrogen or halogen atom, an NH 2 , NHR 2 , NHCOR 2 , NO 2 , CN, CH 2 NH 2 and CH 2 NHR 2 ; or alternatively R 1 represents an optionally substituted phenyl or an optionally substituted heteroaromatic group; Ar represents an optionally substituted phenyl group or an optionally substituted heteroaromatic group; n represents 0, 1, 2 or 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. Application in therapy.

  通用公式（I）对应的化合物：其中，R1代表氢原子或卤素原子，NH2，NHR2，NHCOR2，NO2，CN，CH2NH2和CH2NHR2；或者R1代表可选择取代的苯基或可选择取代的杂环芳基；Ar代表可选择取代的苯基或可选择取代的杂环芳基；n表示0、1、2或3；以碱、与酸的加合盐、水合物或溶剂化合物的形式。在治疗中的应用。
• INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA
  申请人：D'ORCHYMONT Hugues

  公开号：US20070185187A1

  公开（公告）日：2007-08-09

  The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a hydrate or of a solvate of said base or acid addition salt.

  该发明涉及治疗或预防疟疾的方法，包括向需要的患者施用一种通式（I）的1H-吲唑-3-羧酰胺衍生物的有效量，其为碱式或与酸形成的加合盐的形式，或为所述碱式或酸性加合盐的水合物或溶剂化合物的形式。
• [EN] COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OR DISORDERS ASSOCIATED WITH MISREGULATED EIF4E<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT DE TRAITER OU DE PRÉVENIR DES MALADIES OU AFFECTIONS ASSOCIÉES À UNE MAUVAISE RÉGULATION DE EIF4E
  申请人：EGENIX INC

  公开号：WO2014066304A1

  公开（公告）日：2014-05-01

  Disclosed herein are compounds, compositions, formulations, kits and methods of treatment useful for treating or preventing one or more hyperproliferative disorders, e.g., cancer or a neurological disease or disorder.

  本文揭示了一些化合物、组合物、配方、试剂盒和治疗方法，可用于治疗或预防一个或多个过度增殖性疾病，例如癌症或神经系统疾病或障碍。
• [EN] 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS<br/>[FR] COMPOSES 1H-INDAZOLE-3-CARBOXAMIDE UTILISES COMME MODULATEURS DE LA MAPKAP KINASE
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005014554A1

  公开（公告）日：2005-02-17

  The invention provides compounds of the formula: (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a MAPKAP kinase: wherein A is a bond or a group CH2; R1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; R3, R4, R5 and R6 are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra -Rb wherein Ra is a bond, 0, CO, X1C(X2), C(X2)Xl, X1C(X2)X1, S, SO, S02, NRc, SO2NRc or NRcS02; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by 0, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; Rc is hydrogen or C1-4 hydrocarbyl; and X1 is O, S or NRc and X2 is =O, =S or =NRc.

  该发明提供了化合物的公式：（I），用于预防或治疗由MAPKAP激酶介导的疾病状态或病情：其中A是键或CH2基团; R1是具有3到12个环成员的碳环或杂环基团; R3，R4，R5和R6相同或不同，每个都选择自氢，卤素，羟基，三氟甲基，氰基，硝基，羧基，氨基，碳环和具有3到12个环成员的杂环基团中的一个; Ra-Rb基团，其中Ra是键，0，CO，X1C（X2），C（X2）Xl，X1C（X2）X1，S，SO，S02，NRc，SO2NRc或NRcS02; Rb选择自具有3到12个环成员的氢，碳环和杂环基团，以及C1-8烃基，可选地被一个或多个选择自羟基，氧化物，卤素，氰基，硝基，单或双C1-4烃基胺基，具有3到12个环成员的碳环和杂环基团的取代基取代，并且C1-8烃基的一个或多个碳原子可以选择性地被0，S，SO，SO2，NRc，X1C（X2），C（X2）X1或X1C（X2）X1取代; Rc是氢或C1-4烃基; X1是O，S或NRc，X2是=O，=S或=NRc。